Technology for sensitive and reliable mutational profiling in pancreatic cancer

胰腺癌敏感且可靠的突变分析技术

基本信息

  • 批准号:
    7626951
  • 负责人:
  • 金额:
    $ 22.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-01 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Mutational profiling of pancreatic cancer holds major promise for early detection, prognosis and therapeutic management of this disease. However, as with many other cancers, while reliable screening methods for germline or prevalent somatic mutations already exist, detection of low-prevalence somatic mutations in heterogeneous, multifocal pancreatic cancers with stromal contamination, or in bodily fluids remains problematic. Thus, for a substantial fraction of clinical pancreatic cancer samples, the new powerful mutation detection technologies "lose steam" and their advantages cannot be exploited. We developed co-amplification at lower denaturation temperature polymerase chain reaction (COLD-PCR), a new form of PCR that amplifies preferentially the "minority alleles" from mixtures of wild-type and mutation-containing sequences, irrespective of where the mutation lies, providing a 10-100-fold enrichment of the mutated sequences during PCR. Because PCR comprises the ubiquitous first step in genetic analysis, COLD-PCR provides a general platform to improve sensitivity for essentially all diagnostic assays. In this application we propose to develop further, optimize and adapt COLD-PCR for increasing the sensitivity of two established mutation detection methods, such that they can be applied for reliable identification of clinically-relevant, somatic mutations in heterogeneous, multifocal pancreatic cancers: matrix assisted laser desorption ionization-time of flight (MALDI-TOF) for known mutations, and single molecule sequencing for high-throughput sequencing of somatic mutations. The combination of COLD-PCR with these two technologies, each tackling a different aspect of mutation detection, will boost the sensitivity of patient- specific mutational profiling, and is suited for application to pancreatic cancer. A comprehensive list of genes mutated in pancreatic cancers will be compiled and COLD-PCR will be adapted for parallel screening of somatic mutations in pancreatic surgical specimens and plasma samples using the selected technologies. In the forthcoming era of molecular medicine, clinical decisions will increasingly rely on molecular tumor profiling, and the reliability of identifying somatic mutations in diverse clinical specimens must be high. This application tackles the problem of molecular analysis in heterogeneous cancers. We focus the new technology on pancreatic cancer, a heterogeneous cancer that currently has very low cure rates and for which molecular biomarkers can make a difference.
描述(由申请人提供):胰腺癌的突变谱分析对这种疾病的早期发现、预后和治疗管理具有重要的前景。然而,与许多其他癌症一样,虽然已经存在可靠的生殖系或普遍体细胞突变筛查方法,但在异质性、多灶性间质污染胰腺癌或体液中检测低患病率体细胞突变仍然存在问题。因此,对于相当一部分临床胰腺癌样本,新的强大的突变检测技术“失去了动力”,其优势无法发挥。我们开发了低变性温度下的共扩增聚合酶链反应(COLD-PCR),这是一种新的PCR形式,可以优先扩增野生型和含突变序列混合物中的“少数等位基因”,而不管突变位于何处,在PCR过程中突变序列的富集程度可达10-100倍。因为PCR是基因分析中普遍存在的第一步,COLD-PCR提供了一个通用的平台,以提高基本上所有诊断分析的敏感性。在这项应用中,我们建议进一步发展、优化和适应COLD-PCR,以提高两种已建立的突变检测方法的灵敏度,使它们能够用于可靠地鉴定异质多灶胰腺癌中与临床相关的体细胞突变:基质辅助激光脱吸电离飞行时间(MALDI-TOF)用于已知突变,单分子测序用于体细胞突变的高通量测序。COLD-PCR与这两种技术的结合,各自处理突变检测的不同方面,将提高患者特异性突变谱的敏感性,适合应用于胰腺癌。将编制一份胰腺癌突变基因的综合清单,并使用选定的技术将COLD-PCR应用于胰腺手术标本和血浆样本的体细胞突变平行筛选。在即将到来的分子医学时代,临床决策将越来越依赖于分子肿瘤谱分析,在不同的临床标本中识别体细胞突变的可靠性必须很高。这个应用程序解决了异质性癌症分子分析的问题。我们将新技术的重点放在胰腺癌上,这是一种异质性癌症,目前治愈率非常低,分子生物标志物可以发挥作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

G. Mike Makrigiorgos其他文献

G. Mike Makrigiorgos的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('G. Mike Makrigiorgos', 18)}}的其他基金

Comprehensive minimal residual disease tracking in cancer
癌症的全面微小残留病追踪
  • 批准号:
    9920128
  • 财政年份:
    2018
  • 资助金额:
    $ 22.7万
  • 项目类别:
Maximum efficiency sequencing using nuclease-based mutation enrichment and digital barcodes
使用基于核酸酶的突变富集和数字条形码进行最高效率测序
  • 批准号:
    9355330
  • 财政年份:
    2017
  • 资助金额:
    $ 22.7万
  • 项目类别:
Prognostic potential of low-level mutations in meylodysplastic syndrome
骨髓增生异常综合征低水平突变的预后潜力
  • 批准号:
    8787719
  • 财政年份:
    2014
  • 资助金额:
    $ 22.7万
  • 项目类别:
Mutation Enriched Targeted Re-Sequencing
突变富集靶向重测序
  • 批准号:
    9195704
  • 财政年份:
    2013
  • 资助金额:
    $ 22.7万
  • 项目类别:
Temperature-Tolerant COLD-PCR enables mutation-enriched targeted re-sequencing
耐温 COLD-PCR 可实现突变富集的靶向重测序
  • 批准号:
    8591934
  • 财政年份:
    2013
  • 资助金额:
    $ 22.7万
  • 项目类别:
High-throughput technology that enables sequencing depth for colorectal CA
高通量技术可实现结直肠 CA 深度测序
  • 批准号:
    8333344
  • 财政年份:
    2011
  • 资助金额:
    $ 22.7万
  • 项目类别:
High-throughput technology that enables sequencing depth for colorectal CA
高通量技术可实现结直肠 CA 深度测序
  • 批准号:
    8153972
  • 财政年份:
    2011
  • 资助金额:
    $ 22.7万
  • 项目类别:
Technology for sensitive and reliable mutational profiling in pancreatic cancer
胰腺癌敏感且可靠的突变分析技术
  • 批准号:
    7795122
  • 财政年份:
    2009
  • 资助金额:
    $ 22.7万
  • 项目类别:
Technology for sensitive and reliable mutational profiling in pancreatic cancer
胰腺癌敏感且可靠的突变分析技术
  • 批准号:
    8022903
  • 财政年份:
    2009
  • 资助金额:
    $ 22.7万
  • 项目类别:
CIRCULATING DNA AMPLIFICATION & COLON CA DETECTION
循环 DNA 扩增
  • 批准号:
    7090955
  • 财政年份:
    2006
  • 资助金额:
    $ 22.7万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 22.7万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 22.7万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 22.7万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 22.7万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 22.7万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 22.7万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 22.7万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 22.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 22.7万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 22.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了